SUN PHARMA: Regulators Halt Eye Drop Production at Assam

Indian drug regulators have directed

to suspend the manufacturing, sale and distribution of ophthalmic products at its Assam facility following serious quality-control lapses identified during a joint inspection by CDSCO and Assam drug authorities in August. KEY DEVELOPMENTS 🔹 Regulatory Action: Production and distribution of ophthalmic products at the Assam plant have been stopped after inspectors identified significant deficiencies in quality management systems and confirmed bacterial contamination in sealed medicine bottles. 🔹 Product Recall: Sun Pharma had voluntarily withdrawn approximately 332 batches across 11 ophthalmic brands in July as a precautionary measure. 🔹 Affected Products: The recalled formulations include Lotepred 1%, Nepaflac OD, Nepaflac-Z, Brinzotim and Depopred. 🔹 Patient Safety Concerns: Reports of eye infections and contamination in unopened bottles have intensified regulatory scrutiny over the company's sterile manufacturing processes. 🔹 Compliance Review: Sun Pharma has submitted a corrective action and compliance report, which is currently being examined by regulators. Restarting operations will depend on satisfactory verification of corrective measures. MARKET TAKEAWAY The regulatory action raises concerns over Sun Pharma's manufacturing quality standards and compliance processes. Investors will closely monitor the company's corrective measures, regulatory clearance and potential business impact. #SunPharma #SunPharmaceuticals #PharmaSector #CDSCO #DrugRegulation #PharmaceuticalIndustry #QualityControl #StockMarket #NSE #BSE #NiveshResearch Investment in securities market are subject to market risks. Read all the related documents carefully before investing.